Brim Healthcare

Brim Biotechnology is a clinical-stage biopharmaceutical company based in Taiwan, specializing in the development of novel regenerative therapies for ophthalmology and degenerative diseases. The company's core technology is the Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) platform, which leverages the multi-functional properties of the PEDF protein to promote tissue repair and wound healing. Its lead candidate, BRM421, is a first-in-class synthetic peptide currently in Phase 3 clinical trials for the treatment of dry eye syndrome, demonstrating a rapid onset of action in improving both signs and symptoms. Beyond ophthalmology, Brim is expanding its pipeline into indications such as neurotrophic keratitis, osteoarthritis, and androgenetic alopecia. The company is listed on the Taiwan Emerging Stock Market and aims to address significant unmet needs through its innovative peptide-based approach.